Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.

OUR RELATIONSHIPS

our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.

OUR TRACK RECORD

our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.

4-Antibody AG

Sale to Agenus

$40 million+ with $10mm upfront

January 2014

Europe

Teva

Sale of 31 ANDAs to ANI Pharmaceuticals

$12.5mm + Profit Share

December 2013

Asia, Africa, MidEast, Latin America

Pinnacle Biologics

Sale to Concordia Healthcare

December 2013

North America

April 5-9, 2014

AACR – American Association for Cancer Research – Annual Meeting

San Diego, CA

April 8-9, 2014

BIO Asia International Conference

Tokyo, Japan

May 12-14, 2014

Biotrinity (OBN)

London, UK

February 19, 2014

Torreya Partners Announces Three Executive Promotions

MORE

November 25, 2013

Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer

MORE

November 18, 2013

Cardiome acquires Correvio LLC

MORE